HC Wainwright & Co. Reiterates Buy on BioXcel Therapeutics, Maintains $10 Price Target

Benzinga · 05/10 11:57
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates BioXcel Therapeutics (NASDAQ:BTAI) with a Buy and maintains $10 price target.